This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Nuvo Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 1/6
Key information
1,149.7%
Debt to equity ratio
CA$97.55m
Debt
| Interest coverage ratio | 1.3x |
| Cash | CA$31.26m |
| Equity | CA$8.49m |
| Total liabilities | CA$118.77m |
| Total assets | CA$127.26m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 23N's short term assets (CA$51.8M) exceed its short term liabilities (CA$24.6M).
Long Term Liabilities: 23N's short term assets (CA$51.8M) do not cover its long term liabilities (CA$94.2M).
Debt to Equity History and Analysis
Debt Level: 23N's net debt to equity ratio (781.3%) is considered high.
Reducing Debt: 23N's debt to equity ratio has increased from 0% to 1149.7% over the past 5 years.
Debt Coverage: 23N's debt is not well covered by operating cash flow (15.9%).
Interest Coverage: 23N's interest payments on its debt are not well covered by EBIT (1.3x coverage).